Skip to Content Skip to Search

Innovation

How our R&D approach helps us get Ahead Together

Innovation is at the heart of achieving our purpose – to unite science, technology and talent to get ahead of disease together.

We’re combining the power of genetic and genomic insights into what causes disease, with the speed and scale of artificial intelligence and machine learning (AI/ML) to make better predictions about who a treatment might work for, and why.

We believe this powerful combination of data and technology holds the key to fundamentally transforming medical discovery for the better, improving R&D success rates and shaping how even the most challenging diseases, like neurological conditions and cancer, can be both prevented and treated.

There’s never been a time when science and technology have formed such a powerful union as they do now. We’re able to identify drug discovery targets using genomics and AI/ML in a way that is unprecedented. We’re also able to use more approaches than ever before to design new vaccines and medicines to address the root cause of disease.

Portrait of Tony Wood
Tony Wood

Chief Scientific Officer-designate

Our global vaccines US R&D center in Rockville (Maryland) is one of three global vaccines R&D centers, complementing GSK’s centers in Rixensart, Belgium and Siena, Italy. The US center is focused on the discovery and development of vaccines.

Our pharmaceutical R&D facility in Upper Providence (Pennsylvania) is one of two major pharmaceutical R&D hubs for GSK globally, complementing our R&D Center in Stevenage, UK. These hubs focus on research across our four core therapy areas: Infectious diseases, HIV, Oncology and Immunology

We have research centers across the US

  • Branford, CT (ViiV Healthcare) 
  • Cambridge, MA 
  • Richardson, TX 
  • Rockville, MD
  • San Diego, CA 
  • Upper Providence, PA
  • Waltham, MA

Our pipeline

As a global biopharma company, we invest heavily in our industry-leading pipeline of new products and specialty medicines that help us to get ahead of disease together.

Half of a 3D rendering of a Covid virus cell
60+
60+ potential vaccines and medicines
70%+
More than 70% of these products modulate the immune system
x2
Doubled the number of assets in phase III clinical development during last 5 years

Therapeutic areas

We prioritize innovation to make the world’s diseases a thing of the past. 

To get ahead of disease, we prioritize research into vaccines and medicines across our four therapeutic areas. We also remain open to opportunities outside these core areas where the science aligns with our strategic approach. ​

Explore more about our therapeutic areas on our global website, below.

How we apply technology to get Ahead Together

We are at the forefront of health-related advances in science and technology, working to create innovative solutions to a range of healthcare challenges.

Advanced technology platforms such as AI, machine learning and functional genomics are central to our R&D approach. At the same time, diverse vaccine platform technologies including the use of adjuvants and mRNA technology have the potential to drive the next generation of vaccines and medicines. 

Explore how we apply technology to R&D
alt text

Back to top